COMPOSITION
Ticas® 0.05% cream : Each 100 mg of Ticas® Cream contains 0.05 mg of
Fluticasone propionate.
PHARMACOLOGY
Fluticasone propionate is a glucocorticoid with high topical
after dermal administration. It, therefore, has a therapeutic index which
is
propionate
This
properties of glucocorticoids.
receptor, and
receptors. The therapeutic
Fluticasone propionate
glucocorticoid-receptor complex is approximately 10 hours.
INDICATION
manifestations of corticosteroid-responsive eczema/dermatitis.
DOSAGE AND ADMINISTRATION
CONTRAINDICATION AND PRECAUTION
Fluticasone propionate is contraindicated in Rosacea, Acne vulgaris,
Perioral dermatitis, Primary cutaneous viral infections (e.g., herpes
simplex, chicken pox), Hypersensitivity to any of the ingredients,
Perianal and genital pruritus, etc. The use of Fluticasone propionate is
not indicated in the treatment of primarily infected skin lesions caused
by infection with fungi or bacteria and Fluticasone Propionate Topical
corticosteroid dermatoses in children under one year of age, including
deramtitis and napkin eruptions. Fluticasone propionate has a very
low propensity for systemic absorption, nevertheless, prolonged
application of high doses to large areas of body surface, especially in
infants and small children might lead to adrenal suppression. Children
may absorb proportionally larger amounts of topical corticosteroids
and thus be more susceptible to systemic toxicity. The face, more than
other areas of the body, may exhibit atropic changes after prolonged
treatment with potent topical corticosteroids. This must be borne in
mind when treating severe eczema. Appropriate antimicrobial therapy
should be used whenever treating
infection requires withdrawal of topical
corticosteroid therapy and systemic administration of antimicrobial a
gents. Bacterial infection isencouraged by the warm, moist conditions
induced by occlusive dressing, and so the skin should be cleansed
before a fresh dressing is applied.
SIDE EFFECT
local burning and pruritus have been reported. If signs of
hypersensitivity appear, application should be stopped immediately.
Prolonged and intensive treatment with potent corticosteroid
preparations may cause local atrophic changes in the skin such as
hypertrichosis and hypopigmentation. Secondary infection,
particularly when occlusive dressings are used or when skin folds are
involved and allergic contact dermatitis have also been reported
with corticosteroid use. Exacerbation of the signs and symptoms of
the dermatoses have been reported with corticosteroid use.
Prolonged use of large amounts of corticosteroids, or treatment of
occur in infants and children, and if occlusive dressings are used. In
infants, the napkin may act as an occlusive dressing.
USE IN PREGNANCY AND LACTATION
propionate into human breast milk has not been
investigated. Plasma levels in patients following dermal application
to mother and baby.
OVERDOSE
Acute overdosage is very unlikely to occur, however, in case of cronic
overdosage or misuse the features of hypercorticism may appear,
and in this situation, as with any corticosteroid, application should be
discontinued.
ointment is extremely unlikely to occur due to the very low
STORAGE CONDITION
Store below 30˚C. Do not freeze.
HOW SUPPLIED
Ticas® 0.05% Cream : Tube containing 10 gm of the cream.
source
